Company Overview of Oryzon Genomics S.A.
Oryzon Genomics S.A., a biopharmaceutical company, develops and commercializes biomarkers identified through genomics and proteomics in the fields of diagnostics, personalized medicine, and therapy. Its products pipeline comprises GynEC-DX, a diagnostic test for endometrial cancer; ColoBRAF, a genetic test that verifies the presence of the BRAF-V600E mutation in MSI-H tumors; and Cxbladder, a non-invasive bladder cancer diagnostic test. The company also develops small molecules and monoclonal antibodies for various indications, including leukemia and other cancers, PD/AD and other dementias, Huntington, viral infections, squamous cell cancer, prostate cancer, and endometrial cancer. In addit...
Sant Ferran 74
Cornellà de Llobregat
Founded in 2000
Key Executives for Oryzon Genomics S.A.
Co-Founder, Chairman, Chief Executive Officer, President and Member of Financial Advisory Board
Co-Founder, Scientific Director and Director
Global Chief Financial Officer, Executive Vice President, Director and Chairman of Audit Committee
Chief Intellectual Property Officer
Director of Business Development
Compensation as of Fiscal Year 2015.
Oryzon Genomics S.A. Key Developments
Oryzon Genomics S.A. Is Planning IPO
Sep 17 15
Oryzon Genomics S.A. is seeking investment through an Initial Public Offer on National Securities Market Commission by end of this year. The firm has engaged Solventis A.V., S.A. to coordinate the investment banking and registration listing process. The company also plans to float in Nasdaq by a dual listing in the midterm.
ORYZON Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-08-2015
Sep 5 15
ORYZON Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-08-2015 . Venue: The St. Regis Hotel, Two East 55th Street, New York, NY 10022, United States.
Oryzon Genomics S.A., Special/Extraordinary Shareholders Meeting, Sep 14, 2015
Aug 14 15
Oryzon Genomics S.A., Special/Extraordinary Shareholders Meeting, Sep 14, 2015., at 10:00 Central European Standard Time. Location: registered officeSant Ferran, 74. Agenda: To consider the number of members of the Board of Directors; to consider an appointment and renewal of directors; to consider an approval extent, if any, of the application for admission to trading of the shares of the Company in the continuous market; to consider an determination, where appropriate, the maximum amount of the annual remuneration to be paid to all members of the Board of Directors in financial year 2015; to consider an delegation to the Board of Directors the power to increase capital social under the terms of Article 297.1.b) of the Corporations Act; to consider an Delegation of powers; and to consider an reading and approval, if applicable, of the minutes.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 7, 2015